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Abstract
Purpose p16 overexpression was considered as surrogate marker to identify human papillomavirus (HPV)-associated oro-
pharyngeal squamous cell carcinoma (OPSCCs).
Methods 102 patients with advanced stage OPSCCs treated primarily by transoral lasermicrosurgery were included. Prog-
nostic associations of p16- and HPV-status were analyzed separately and combined.
Results In contrast to p16, the HPV-status resulted in no significant survival discrepancies (5-year overall survival (OS) 
HPV-positive 64.9%, HPV-negative 78.7%). Combining both markers, p16-positive (p16-positive/HPV-positive, p16-positive/
HPV-negative) and p16-negative/HPV-negative groups demonstrated comparable high survival (OS 78.1% vs. 85.6% vs. 
73.6%). Lowest survival was observed for patients with p16-negative/HPV-positive OPSCCs (OS 40.8%).
Never smoking patients with p16-positive OPSCCs demonstrated the highest survival, whereas within former/current smok-
ers with p16-positive and p16-negative disease it was comparable low (OS 90.0% vs. 63.0% vs. 57.4%).
Conclusions p16- and HPV-status should not be considered as equivalent markers for a better prognosis. Furthermore, they 
should not generally predominate patient associated factors like smoking.
Keywords Oropharyngeal squamous cell carcinoma · Oropharyngeal cancer · p16 · Human papillomavirus (HPV) · 
Prognosis · Head and neck squamous cell carcinomas (HNSCC)
Introduction
Oropharyngeal cancer constitutes 11.3% of all head and neck 
malignancies [1]. Apart from the most prevalent risk fac-
tors of alcohol and tobacco consumption [2], a geographi-
cal divergent increasing subset of oropharyngeal squamous 
cell carcinomas (OPSCC) is characterized by human pap-
illomavirus (HPV) infections [3–8]. Most commonly they 
are caused by the HPV-genotype 16 [9] while non-HPV16 
HPV-genotypes were also recognized with a high oncogenic 
potential [10].
In the course of HPV-infection, integration of HPV into 
the host genome results in stabilization and upregulation 
of the viral oncoproteins E6 and E7, E7 binds and leads to 
an inactivation and degradation of tumor suppressive ret-
inoblastoma protein, presumably resulting in an upregula-
tion of the protein p16 [11–15]. The immunohistochemical 
detection of p16-overexpression was associated with a high 
sensitivity to identify samples with oncogenic HPV infec-
tions [16]. Therefore, it was previously used as a surrogate 
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marker for identification of HPV-associated OPSCCs [17, 
18]. Nevertheless, previous studies suggest that the combi-
nation of both markers, p16- and HPV-status, define prog-
nostic divergent subgroups [19–24]. This needs to be con-
sidered, especially since treatment de-intensification trials 
investigated altered therapeutic regimes for HPV-associated 
OPSCCs [17, 25]. Therefore, the aim of the study was to 
examine the prognostic impact of additional HPV diagnos-
tic in a well-characterized and p16-stratified homogenously 
treated cohort of patients with advanced stage OPSCCs.
Patients, material and methods
Patients
A retrospective analysis of patients with advanced stage 
OPSCCs (III-IVa) treatable by transoral  CO2-laser microsur-
gery (TLM) with curative intent was performed. The study 
was conducted at an academic tertiary referral center. Time 
span of inclusion was 01/2000 and 10/2015 with system-
atic follow-up until 10/2017. Cases were identified and data 
were obtained from the hospital’s cancer database and the 
original medical records. This study was approved by the 
institutional review board (“Ethikkommission der Univer-
sitätsmedizin Göttingen”; 10/2/16 An) in accordance with 
the national regulation and with the Helsinki Declaration of 
1975, as revised in 1983. Prior to treatment, all patients gave 
their written informed consent for anonymized analysis of 
their individual data.
Exclusion criteria comprised non-OPSCC, previous or 
simultaneous secondary malignancies, T4b primaries, N3 
metastasis, simultaneous distant metastases, previous treat-
ment of the OPSCC in a different institution, treatment of 
the primary tumor by conventional surgery, flap reconstruc-
tion, primary (chemo-)radiotherapy and palliative treatment 
intent. Of 161 identified patients, 125 had sufficient paraffin 
embedded tissue material available for p16-immunohisto-
chemistry as well as HPV-genotyping. Thereof 23 patients 
were diagnosed with early stage I–II OPSCCs and therefore 
omitted from analysis, resulting a final cohort of 102 patients 
with advanced disease.
Staging and treatment strategy
Preoperative staging procedures were performed as 
described previously [26] according to the 7th edition of 
classification of the Union International Contre le Cancer 
(UICC) [27] and the American Joint Committee on Cancer 
(AJCC) [28].
The therapeutic strategy was TLM-resection of the 
primary tumor with/without neck dissection (ND), with/
without postoperative (chemo-)radiotherapy ((C)RT) as 
described previously [26]. The therapeutic approach was not 
based upon the diagnosis of HPV- or p16-status. In all cases 
histopathological assessment confirmed margin-negative 
(R0) resection.
Follow‑up
The postoperative examination and follow-up was performed 
as previously described [26]. After 5 years without disease 
manifestations a patient was considered cured; however, 
follow-up continued in most cases.
Molecular diagnostics—p16 and HPV
p16 immunohistochemistry was performed with monoclo-
nal p16 antibodies (Santa Cruz Biotechnology, Inc., Dal-
las, TX, USA; Cat# sc-56330) (1:50; pH 9) in combination 
with diaminobenzidine (Dako, Agilent Technologies, Inc., 
Santa Clara, California), and the EnVision Flex + System 
(Dako, Agilent Technologies, Inc.). A strong diffuse (≥ 75%) 
nuclear and cytoplasmic p16 immunostaining was catego-
rized as p16-positive. No, weak, or moderate staining was 
considered as p16-negative [18, 29].
For multiplex fluorescent-PCR based detection of DNA 
from different HPV genotypes a commercial assay devel-
oped for diagnostic purposes was applied. Formalin-fixed 
paraffin-embedded (FFPE) tissue samples of the oro-
pharyngeal primaries were used. A 5 µm FFPE slice was 
enriched for tumorous tissue by microdissection and DNA 
was isolated with the innuPREP FFPE DNA Kit—IPC16 
(Analytik Jena AG, Jena, Germany) in combination with the 
InnuPure® C16 touch (Analytik Jena AG, Jena, Germany). 
Quantification and purity of the isolated DNA was measured 
by a NanoDrop™ 2000 Spectrophotometer (Thermo Fischer 
Scientific Inc., Waltham, MA, USA). DNA was amplified 
using the f-HPV-typing™ Multiplex Fluorescent-PCR Kit 
according to manufacturer’s protocol (Genomed LTD., Har-
row, Middlesex, UK). The PCR reagent contains 16 fluo-
rescently labelled primers designed to recognize E6 and E7 
regions of HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, and 68 that are most likely present after viral 
integration. The f-HPV-typing™ also contains a human 
short tandem repeat, which serves as an internal control 
[30]. HPV amplicons were separated and measured by the 
Applied Biosystems® 3500 Genetic Analyzer and analyzed 
via GeneMapper™ Software 5 (Thermo Fisher Scientific 
Inc., Waltham, MA, USA).
Alcohol and tobacco consumption
Information about alcohol and tobacco consumption was 
extracted from the original medical records. Both variables 
were categorized dichotomously. Patients self-reporting 
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former/current versus no tobacco consumption were 
assigned to the respective groups. Heavy drinkers were 
defined as patients who had reported at least weekly strong 
or daily other alcohol consumption and/or who had a disease 
related to heavy alcohol consumption (e.g. Wernicke–Korsa-
kow syndrome). Patients self-reporting occasional, limited 
or no alcohol consumption were assigned to the group of 
never/social drinking patients. Cases without information 
on alcohol and/or tobacco consumption were omitted from 
the subanalysis.
Statistics
Descriptive analysis was stated by the respective mean 
value, corresponding standard deviation (SD), median and/
or absolute and relative frequencies. Analysis of frequency 
distributions was conducted with the Pearson’s Chi-squared 
test. Five-year overall survival (OS), disease-specific sur-
vival (DSS), recurrence-free survival (RFS), and the local 
control rate (LCR) were calculated by the Kaplan–Meier 
method [31]. Date of primary surgery was defined as the 
starting point for these calculations. Concerning OS, death 
for any reason was considered as an event, whereas patients 
alive at last follow-up were included as censored observa-
tions. Calculating DSS, only death related to the primary 
tumor was considered as event, and all other causes of death 
were counted as censored observations as well as alive at 
last follow-up. For RFS, events were local and/or regional 
recurrence, occurrence of distant metastasis or death related 
to primary disease, whereas death due to other causes, and 
patients alive without manifestation of the primary tumor at 
last follow-up were considered as censored. Regarding LCR, 
exclusively local recurrences were determined as events. The 
log-rank test was applied to assess statistically significant 
survival differences between groups. Kaplan–Meier curves 
were applied to illustrate survival differences. The level of 
significance was defined at 5%. Statistical analysis and crea-
tion of Kaplan–Meier curves were performed with Statis-
tica, Version 13.3 (Dell Inc., Round Rock, TX, USA). For 
adjustment of potential cofounding factors, Cox multivariate 
regression analysis (forward stepwise) was conducted with 
IBM SPSS® Statistics, Version 26.0 (IBM Corp, Armonk, 
NY, USA). p16- and HPV-status as separate covariates or 
the combination of both markers was analyzed together with 
gender, age (continuous), T-categorization (T1-2 vs. T3-T4), 
lymph node metastases (N0 vs. N+), extracapsular spread 
(N0/N+ ECS- vs. N+ ECS+), staging (III vs. IVa), histo-
pathologic differentiation (high/moderate vs. poor), treat-
ment (TLM +/-ND vs. TLM+ND+(C)RT). Additionally, 
within the cohort with available information about alcohol 
and tobacco consumption, these variables were also consid-
ered. For final editing Adobe Illustrator® CC, Version 18.1 
(Adobe Systems Inc., San José, CA, USA) was applied.
Results
Patients
102 patients with advanced stage OPSCC (pT3-4a and/or 
pN + ; stage III/IVa) were included in the study. The site of 
primary origin of oropharyngeal tumors was 40.2% (n = 41) 
tonsils, 25.5% (n = 26) tongue base, 3.9% (n = 4) soft pal-
ate, 12.7% (n = 13) vallecula, 3.9% (n = 4) posterior wall, 
3.9% (n = 4) lateral wall, 5.9% (n = 6) glossotonsillar sulcus 
and palatal arch, 2.9% (n = 3) uvula, and 1% (n = 1) tonsillar 
fossa. All patients were treated primarily by TLM. It was 
completed with neck dissection in 96.1% (n = 98) and post-
operative (chemo)radiotherapy in 73.5% (n = 75).
p16 expression and HPV‑typing results
p16-overexpression was seen in 49.0% (n = 50) of all tumors. 
HPV-DNA was detected in 40.2% (n = 41) of all OPSCCs. 
Distribution of p16-status and HPV-typing results are 
depicted in Table 1. In most of these cases, HPV-genotype 
16 was detected. With regard to all HPV-DNA positive spec-
imens, HPV16 was found in 80.5% (n = 33), HPV18 in 7.3%, 
(n = 3), HPV33 in 26.8% (n = 11), HPV51 in 2.4% (n = 1) 
and HPV59 in 19.5% (n = 8). In most of the tumors one 
single HPV-type was identified (n = 31; 75.6%). Most com-
monly it was HPV16 (n = 23; 56.1%). The majority of these 
OPSCCs with selective HPV16 infection showed p16-over-
expression (n = 20; 87.0%). Multiple HPV infections were 
detected in 24.4% (n = 10) of all HPV-positive specimens. 
Worthy of note, all of them also exhibited HPV16, while 
only 30.0% (n = 3) of them showed a p16-overexpression.
Concordance between p16-immunostatus and presence of 
HPV-DNA was observed in 63.7% (n = 65), presenting either 
as p16-positive and HPV-DNA-positive (n = 27; 26.5%) or 
p16-negative and HPV-DNA-negative (n = 38; 37.3%). Con-
tradictory results were found in 36.3% (n = 37). p16-positive 
with no presence of HPV-DNA (p16-positive/HPV-negative) 
were 22.5% (n = 23) of the OPSCCs. Vice versa 13.7% 
(n = 14) were p16-negative and positive for HPV-DNA 
(p16-negative/HPV-positive). Among p16-positive OPSCCs 
the presence of HPV-DNA and, therefore, concordance of 
p16- and HPV-positivity was 54.0% (n = 27 of 50).
Disease characteristics
Patients’ and disease characteristics, treatment details and 
follow-up data of the whole study group as well as stratified 
by p16-status, HPV-status and the resulting subgroups with 
both markers combined are depicted in Table 2. As shown, 
distribution analysis of characteristics between patients 
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stratified by either (1) p16-immunohistochemistry, or (2) 
HPV-typing, or (3) both markers combined, revealed no sig-
nificant difference in reference to gender, N-category, pres-
ence of lymph node metastases with extracapsular spread, 
prognostic stage and treatment (Pearson’s Chi-squared 
test P > 0.1 respectively). However, T-categories were sig-
nificantly differently distributed between p16-positive and 
p16-negative OPSCCs (P < 0.01). p16-negative tumors 
were more often diagnosed in a higher T-category (pT3/
pT4: n = 40 of 52; 76.9%) compared to p16-positive tumors 
(n = 24 of 50; 48.0%). A significant different distribution of 
T-categories was also observed, when taking both markers 
combined into account (P = 0.02). Concordant p16-nega-
tive/HPV-negative cases were more often locally advanced 
tumors (pT3/pT4a: n = 29 of 38, 76.3%) and concordant 
p16-positive/HPV-positive cases presented more often 
as locally circumscribed tumors (pT1/pT2: n = 16 of 27, 
59.3%). Furthermore, histopathological differentiation was 
significantly differently distributed between p16-positive 
and p16-negative tumors (high/moderate vs. poor: P = 0.01). 
Most of p16-negative OPSCCs had a high or moderate dif-
ferentiation (n = 46 of 52; 88.5%). Most of the poorly dif-
ferentiated tumors were constituted by p16-positive tumors 
(n = 16 of 22; 72.7%).
Tobacco and alcohol consumption were significantly 
differently distributed between patients with p16-positive 
and p16-negative disease, respectively (smoking P < 0.01; 
alcohol P < 0.01). Never smoking patients had more often 
p16-positive tumors (n = 21 of 26; 80.8%), whereas former/
current smokers had more often p16-negative ones (n = 43 
of 62; 69.4%). Furthermore, no/social drinking patients had 
predominantly p16-positive disease (n = 34 of 53; 64.2%), 
whereas those with heavy alcohol consumption had more 
p16-negative cancers (n = 28 of 33; 84.8%). With regard 
to the HPV-status, no significant different distribution was 




Local and/or regional treatment failures were diagnosed in 
18.6% (n = 19) of all patients. The occurrence of treatment 
failures was not differently distributed between patients with 
p16-positive versus those with p16-negative (P = 0.24) or 
HPV-positive versus HPV-negative (P = 0.48) OPSCCs. No 
significant difference was observed including both markers 
combined (P = 0.08).
Details of the treatment failures, occurrence of distant 
metastases and secondary primaries stratified by p16- and 
HPV-status and the marker-combined subgroups are pro-
vided in Table 3.
Survival estimates
All patients included had advanced stage oropharyngeal can-
cer (stage III–IVa). The 5-year estimates of the complete 
cohort were as followed: OS 73.3%, DSS 78.3%, RFS 69.8% 
and LCR 85.6%.
Comparing the survival of patients with p16-positive or 
negative tumors showed superior estimates for p16-positive 
cases [26]. Within the present study, in addition, the HPV-
status of those patients was investigated. Comparing the sur-
vival of cases with HPV-positive vs. HPV-negative tumors, 
no trends towards a significant difference were observed for 
Table 1  Results of HPV-typing 
stratified by p16-status
HPV Human papillomavirus
HPV-typing Total n(%) p16-immunohistochemistry
p16-positive n (%) p16-negative n (%)
Total 102 (100) 50 (100) 52 (100)
HPV-negative 61 (59.8) 23 (46.0) 38 (73.1)
HPV-positive 41 (40.2) 27 (54.0) 14 (26.9)
 Single infection 31 (75.6) 24 (88.9) 7 (50.0)
  HPV16 23 (56.1) 20 (74.1) 3 (21.4)
  HPV18 1 (2.4) 1 (3.7) 0 (0.0)
  HPV33 3 (7.3) 2 (7.4) 1 (7.1)
  HPV59 4 (9.8) 1 (3.7) 3 (21.4)
 Multiple infections 10 (24.4) 3 (11.1) 7 (50.0)
  HPV16, HPV18, HPV33 1 (2.4) 0 (0.0) 1 (7.1)
  HPV16, HPV18, HPV51 1 (2.4) 0 (0.0) 1 (7.1)
  HPV16, HPV33, HPV59 3 (7.3) 0 (0.0) 3 (21.4)
  HPV16, HPV33 4 (9.8) 2 (7.4) 2 (14.3)
  HPV16, HPV59 1 (2.4) 1 (3.7) 0 (0.0)
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any of the endpoints: OS 64.9% vs. 78.7% (P = 0.46), DSS 
69.3% vs. 84.0% (P = 0.19), RFS 68.2% vs. 71.5% (P = 0.60) 
and LCR 88.8% vs. 84.0% (P = 0.65) for HPV-DNA-pos-
itive vs. HPV-DNA-negative tumors, respectively (Online 
Resource 1). Summarized, prognostic impact has been dem-
onstrated for the p16-status, whereas stratification based on 
the presence of HPV-DNA did not result in significant dis-
crepancies in survival rates.
For the following analysis, the whole study group was 
stratified into four groups based on p16-overexpression and 
HPV-DNA presence. This resulted in the group of p16-pos-
itive/HPV-positive tumors (n = 27, 26.5%), p16-positive/
HPV-negative (n = 23, 22.5%), p16-negative/HPV-positive 
(n = 14, 13.7%), and p16-negative/HPV-negative (n = 38, 
37.3%). Among patients with p16-positive OPSCCs, no 
differences between the estimates of HPV-DNA positive 
or negative tumors were observed (OS 78.1% vs. 85.6%, 
P = 0.73; DSS 81.1% vs. 85.6%, P = 0.97; RFS 82.9% vs. 
72.6%, P = 0.48; LCR 94.7% vs. 85.7%, P = 0.35). Within 
patients with p16-negative tumors, those with p16-nega-
tive/HPV-negative disease demonstrated significant higher 
estimates for both, DSS and RFS, compared to the group 
of patients with p16-negative/HPV-positive disease (DSS 
82.6% vs. 47.6%, P = 0.02; RFS 71.2% vs. 42.9%, P = 0.04). 
The OS was 73.6% vs. 40.8% (P = 0.15), and the LCR was 
83.9% vs. 78.6% (P = 0.50), for the group of p16-negative/
HPV-negative vs. p16-negative/HPV-positive tumors, 
respectively. Considering all four subgroups, OS and DSS 
were the highest in the group with discordant p16-positive/
HPV-negative (OS 85.6%; DSS 85.6%) tumors and the low-
est for those with a p16-negative/HPV-positive disease (OS 
40.8%; DSS 47.6%; Fig. 1a, b). With regard to RFS and LCR 
the highest estimates were calculated for the concordant 
p16-positive/HPV-positive group (RFS 82.9%; LCR 94.7%), 
and still lowest for the p16-negative but HPV-positive one 
(RFS 42.9%; LCR 78.6%; Fig. 1c, d). Altogether, p16-pos-
itive subgroups (p16-positive/HPV-positive, p16-positive/
HPV-negative) always constituted the groups with the high-
est survival estimates. The group of p16-negative/HPV-neg-
ative tumors demonstrated comparable survival. The group 
with the lowest survival for all endpoints was p16-negative/
HPV-positive (Table 4, Fig. 1).
Subgroup analysis of alcohol and tobacco 
consumption
Information about tobacco and alcohol consumption was 
documented for 83.3% (n = 85) of all patients. These patients 
were considered for a further subset analysis.
In reference to tobacco consumption, the majority of 
patients (n = 59 of 85; 69.4%) had reported either current or 
former smoking, whereas 30.6% (n = 26 of 85) had negated 
any smoking history. Most of the never smoking patients 
had p16-positive tumors (21 of 26, 80.8%), whereas the 
group of former/current smokers exhibited predominantly a 
p16-negative disease (41 of 59, 69.5%; P < 0.01). HPV-DNA 
status was not differently distributed between never smoking 
patients (13 of 26; 50.0%) and those with a positive history 
for tobacco consumption (25 of 59, 42.4%; P = 0.51).
With regard to alcohol consumption, 37.6% (n = 32) of 
the patients were categorized as heavy drinkers, whereas 
62.4% (n = 53) had reported no or occasional alcohol con-
sumption and therefore were assigned to the group of never/
social drinking patients. This group predominantly consisted 
of patients with p16-positive tumors (34 of 53, 64.2%), 
whereas heavy alcohol consumption was predominantly 
reported by patients with a p16-negative disease (27 of 32, 
84.4%; P < 0.01). Again, HPV-DNA status was not differ-
ently distributed between never/social drinking patients (27 
of 53; 50.9%) and those with heavy alcohol consumption (11 
of 32, 34.4%; P = 0.14).
Considering both factors combined, 71.8% (61 of 85) 
had a positive history of smoking and/or heavy drinking. 
Most of these patients had p16-negative OPSCCs (41 of 61, 
67.2%), whereas the group of never/social drinking patients 
without a history of tobacco consumption had predominantly 
p16-positive tumors (19 of 24, 79.2%; P < 0.01). Again, 
HPV-DNA detection was not differently distributed between 
never smoking and never/social drinking patients (12 of 
24; 50.0%) and smokers and/or heavy drinkers (26 of 61, 
42.6%; P = 0.54). In summary, the distribution of tobacco 
and/or heavy alcohol consumption differed only signifi-
cantly between patients with p16-positive and p16-negative 
disease.
Survival estimates by subgroups of alcohol 
and tobacco consumption
In a subset of 85 patients with documented history of 
tobacco and alcohol consumption the estimates for OS, 
DSS, RFS and LCR accounted for 69.8%, 75.7%, 69.1% and 
88.7%, respectively.
The group of never-smoking patients revealed signifi-
cant superior estimates for OS and DSS compared to the 
group of former/current smokers (OS 91.7% vs. 59.3%, 
P < 0.01; DSS 91.7% vs. 67.5%, P < 0.01). The estimates 
of RFS and LCR for never smoking patients and those 
with a smoking history showed no significant difference 
(RFS 74.4% vs. 66.8%, P = 0.28; LCR 90.5% vs. 88.7%, 
P = 0.51). Further stratification based on p16-status or 
HPV-status within the two groups of never or former/
current smoking patients demonstrated that never smok-
ing patients with p16-positive tumors had favorable OS, 
DSS and RFS compared to former/current smokers with 
a p16-negative disease (OS 90.0% vs 57.4%; DSS 90.0% 
vs 67.8%; RFS 84.2% vs 66.0%). In contrast, the group 
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of p16-positive cancer patients that shared the history of 
former/current smoking demonstrated comparable low 
survival (OS 63.0%, DSS 66.7%, RFS 68.2%; Fig. 2a–c). 
Regarding LCR, estimates were less divergent between 
these groups (94.1% vs. 86.5% vs. 93.8%; Fig. 2d).
Within the two groups of never or former/current smok-
ing patients, stratification upon HPV-status did not demon-
strate prognostic differences (Online Resource 2).
Summarized, never smoking patients with p16-positive 
disease showed the highest survival, whereas former/cur-
rent smokers demonstrated a comparable inferior survival, 
despite the p16-status.
With regard to drinking habits, there was no statistical sur-
vival difference between never/social drinking patients and 
heavy drinkers (OS: 71.5% vs. 67.2%, P = 0.741; DSS: 79.0% 
vs. 70.7%, P = 0.242; RFS: 66.5% vs. 73.8%, P = 0.768; LCR: 
88.0% vs. 89.9%, P = 0.953). Therefore, this factor was not 
considered for further subgroup analysis stratified on p16- or 
HPV-status.
Fig. 1  Five-year Kaplan–Meier estimates of overall survival (a), disease-specific survival (b), recurrence-free survival (c) and local control rate 
(d) stratified by p16- and HPV-status combined. Patients at risk are shown below the diagram. P values are calculated by log-rank test
 European Archives of Oto-Rhino-Laryngology
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Table 4  Overview of studies evaluating five-year oncological outcomes for patients with OPSCC with known p16- and HPV-status treated with 
curative intent
Study Groups Stage [%] Therapyb Total [n] OS [%] DSS [%] RFS [%] LCR [%]
Present study Complete cohort III/IVa = 100 1 102 73.3 78.3 69.8 85.6
p16-positive [26] 50 83.2 84.9 77.1 89.5
p16-negative [26] 52 63.1 71.3 62.5 82.4
HPV-positive 41 64.9 69.3 68.2 88.8
HPV-negative 61 78.7 84 71.5 84
p16-positive/HPV-positive 27 78.1 81.1 82.9 94.7
p16-positive/HPV-negative 23 85.6 85.6 72.6 85.7
p16-negative/HPV-positive 14 40.8 47.6 42.9 78.6
p16-negative/HPV-negative 38 73.6 82.6 71.2 83.9
Smoking/alcohol  consumptiona 85 69.8 75.7 61.1 88.7
Never  smokinga 26 91.7 91.7 74.4 90.5
Former/current  smokera 59 59.3 67.5 66.8 88.7
Never  smokinga, p16-positive 21 90 90 84.2 94.1
Never  smokinga, p16-negative 5 100 100 40 75
Former/current  smokera, p16-positive 18 63 66.7 68.2 93.8
Former/current  smokera, p16-negative 41 57.4 67.8 66.0 86.5
Never  smokinga, HPV-positive 13 80 80 72.7 90.0
Never  smokinga, HPV-negative 13 100 100 75 90.9
Former/current  smokera, HPV-positive 25 55.6 62.8 64.5 91.3
Former/current  smokera, HPV-
negative
34 62.1 71.2 68.5 100
No/social  drinkera 53 71.5 79 66.5 88
Heavy  drinkera 32 67.2 70.7 73.8 89.9
Yamashita et al. [20] Complete cohort I–II = 16
III–IVa = 72
IVb = 12









p16-negative subgroup 66 62.2
 < 40py, p16-positive 26 96




p16-positive/HPV-negative n = 0
p16-negative/HPV-positive 14 57.1
p16-negative/HPV-negative 52 63.9
Yamamoto et al. [26] Complete cohort III/IV = 100 3 107
RT alone 3.1 43 67
RT alone, p16-positive/HPV-positive 19 84
RT alone, p16-positive/HPV-negative 7 57
RT alone, p16-negative/HPV-negative 17 51
CRT 3.2 64 68
CRT, p16-positive/HPV-positive 26 88
CRT, p16-positive/HPV- negative 7 71
CRT, p16-negative/HPV-negative 31 51
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OPSCC  oropharyngeal squamous cell carcinoma, HPV  human papillomavirus, OS overall survival, DSS disease-specific survival, RFS recur-
rence-free survival, LCR local control rate, RT radiotherapy, py pack year
a Patients with known alcohol and tobacco consumption.
b Treatment approaches: 1, transoral laser microsurgery (TLM) + / − neck dissection (ND) + / − (chemo)radiotherapy ((C)RT); 2, primary CRT 
or curative surgery; 3, primary (C)RT; 3.1, primary RT; 3.2, primary CRT; 4, RT ± chemotherapy or cetuximab or brachytherapy ± ND or sur-
gery ± RT; 5, surgery + ND ± (C)RT or non-surgical treatment/(C)RT)
Table 4  (continued)
Study Groups Stage [%] Therapyb Total [n] OS [%] DSS [%] RFS [%] LCR [%]



















 ≤ 10 py 36 83.3
 > 10 py 90 59.6
 ≤ 10py, HPV-DNA-positive 25 96
 ≤ 10py, HPV-DNA-negative 11 54.5
 > 10 py, HPV-DNA-positive 28 66.7
 > 10 py, HPV-DNA-negative 62 56.5
 ≤ 10 py, HPV-RNA-positive 21 100
 ≤ 10 py, HPV-RNA-negative 15 60
 > 10 py, HPV-RNA-positive 26 64
 > 10 py, HPV-RNA-negative 64 57.8
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Analysis of potential cofounders and cox 
multivariate regression
In order to identify potential prognostic relevant cofound-
ers, the association between prognostic endpoints and fur-
ther clinicopathological characteristics were analyzed. The 
results of these univariate analyses are shown in Online 
Resource 3.
For adjustment of potential cofounding factors, also a 
Cox multivariate regression analysis (forward stepwise) 
was conducted. Regarding the complete cohort, in the 
final equation of OS the p16-status (HR = 0.41, 95% CI, 
0.19–0.887, P = 0.023) and extracapsular spread (HR = 2.1, 
95% CI 1.009–4.372, P = 0.047) were included. For DSS, 
extracapsular spread was included in the final model 
when considering p16-status and HPV-status separately 
(HR = 2.768, 95% CI 1.088–7.038, P=0.033). For RFS and 
LCR no significant covariate was identified, respectively.
Considering the combination of p16 and HPV, results of 
the multivariate analysis demonstrated that the combined 
p16/HPV-status and ECS had an impact on OS (ECS: 
HR=2.254, 95% CI 1.067-4.765, P=0.033; combined 
p16/HPV-status: p16-negative/HPV-negative (reference), 
P=0.036, p16-positive/HPV-positive: HR=0.525, 95% 
CI 0.182-1.516, P=0.234, p16-positive/HPV-negative: 
HR=0.534, 95% CI 0.183-1.559, P=0.251, p16 negative/
HPV positive: HR=2.151, 95% CI 0.854-5.417, P=0.104) 
and likewise DSS (ECS: HR=2.951, 95% CI 1.147-7.593, 
Fig. 2  Five-year Kaplan–Meier estimates of overall survival (a), 
disease-specific survival (b), recurrence-free survival (c) and local 
control rate (d) stratified by tobacco consumption and p16-status 
combined. Patients at risk are shown below the diagram. P values are 
calculated by log-rank test
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P=0.025; combined p16/HPV-status: p16-negative/
HPV-negative (reference), P=0.017; p16-positive/HPV-
negative: HR=0.657, 95% CI 0.157-2.757, P=0.566; p16 
negative/HPV positive: HR=0.837, 95% CI 0.198-3.529, 
P=0.808; p16-negative/HPV-positive: HR=3.923, 95% 
CI 1.239-12.416, P=0.02). For RFS, T-categorization 
was in addition to the combined p16-HPV-status included 
in the final equation (T-categorization: HR=0.416, 95% 
CI 0.184-0.943, P=0.036; combined p16/HPV-status: 
p16-negative/HPV-negative (reference), P=0.011 p16-pos-
itive/HPV-positive: HR=0.365, 95% CI 0.105-1.26, 
P=0.111; p16-positive/HPV-negative: HR=0.695, 95% 
CI 0.239-2.021, P=0.504; p16-negative/HPV-positive: 
HR=2.676, 95% CI 1.03-6.949, P=0.043). For LCR no 
significant covariate was identified.       
Considering the cohort with information about alcohol 
and tobacco consumption neither p16-nor HPV-status or 
both combined were associated with one of the prognostic 
endpoints in the univariate analyses (Online Resource 3). 
Consistent with this, in the multivariate Cox regression anal-
ysis only extracapsular spread as well as tobacco consump-
tion were identified to effect OS (ECS: HR = 2.323, 95% CI 
1.066–5.06, P = 0.034; tobacco consumption: HR = 4.403, 
95% CI 1.317–14.717, P = 0.016) as well as DSS (ECS: 
HR = 3.197, 95% CI 1.154–8.855, P = 0.025; tobacco con-
sumption: HR = 8.348, 95% CI 1.1–63.329, P=0.04). For 
RFS and LCR no significant covariate was identified.
Complementary analyses for patients with OPSCCs 
of sublocations, with a potential carcinogenic role 
of HPV (tonsils, base of tongue)
The classification algorithms of the current (8th) edi-
tion of the AJCC/UICC cancer staging manual differ-
entiate between p16-positive and p16-negative OPSCCs 
but not between tonsillar/tongue base OPSCC vs. other 
OPSCC sublocations [5, 18]. Nevertheless, studies indi-
cated an etiological link especially between HPV presence 
and OPSCCs of the tonsillar region and base of tongue 
[32–35]. Therefore 74 patients with tumors, that originated 
from tonsillar regions (ICD-10-GM Version 2020 C09.-, 
n=48) or base of tongue (ICD-10-GM Version 2020 C01, 
n=26) were identified for complementary subset analyses. 
The detailed results are provided in the Online Resources 
4–6 (Tables) and 7–8 (Figures).
p16 positive tumors were significantly more often local-
ized in the tonsillar region or base of tongue (Pearson’s 
chi-squared test, P < 0.01). In contrast the HPV was not 
significantly differentially distributed between tonsillar/
tongue base OPSCC compared OPSCCs of other subloca-
tions (Pearson’s chi-squared test, P = 0.308). There was 
no significant prognostic difference between patients with 
tonsillar/tongue base OPSCC compared to patients with 
OPSCCs of the other sublocations (OS, P = 0.506; DSS, 
P=0.929; RFS, P = 0.806; LCR, P = 0.138). Consistent 
with results the complete cohort, exclusively the p16-sta-
tus (OS, P = 0.014; DSS, P = 0.021; RFS, P = 0.025; 
LCR, P = 0.028), but not the HPV-status (OS, P=0.974; 
DSS, P = 0.837; RFS, P = 0.844; LCR, P = 0.690) was 
associated with significant prognostic discrepancies in 
the univariate analyses of the cohort of tonsillar/tongue 
base OPSCC. Combining both markers, the p16-positive 
(p16-positive/HPV-positive, p16-positive/HPV-negative) 
and p16-negative/HPV-negative groups demonstrated 
comparable superior estimates (OS 81.5% vs. 84.9% vs. 
72.3%; DSS 84.8% vs. 84.9% vs. 76.7%; RFS 85.7% vs. 
71.3% vs. 67.0%; LCR 94.4% vs. 85.0% vs. 77.4%). Low-
est survival was observed for patients with p16-negative/
HPV-positive OPSCCs (OS 42.9%; DSS 42.9%; RFS 
28.6%; LCR 57.1%; Online Resource 7).
Never smoking patients with p16-positive tonsillar/tongue 
base OPSCC demonstrated the best survival, whereas within 
former/current smokers with p16-positive and p16-negative 
disease OS and DSS were comparable low (OS 88.9% vs. 
64.9% vs. 57.8%; DSS 88.9% vs. 69.2% vs. 61.0%; Online 
Resource 8).
Discussion
This study presents a retrospective analysis of the onco-
logical outcome of patients with advanced stage p16-posi-
tive or p16-negative OPSCCs with further examination for 
HPV-DNA. All patients received a TLM-based treatment 
strategy with/without neck dissection, with/without post-
operative (chemo-)radiotherapy between 2000 and 2015 
as described previously [25]. Throughout this time period, 
knowledge about the role of p16-overexpression and asso-
ciation of HPV-infections in head and neck cancer evolved 
[35, 36]. Recently, the p16-status has been introduced in 
the classification algorithm of the 8th edition of the AJCC/
UICC cancer staging manual [5, 18] and trials investi-
gated altered therapeutic regimes for “HPV-associated” 
OPSCCs [17, 34]. Nevertheless, standard treatment recom-
mendations should not yet be altered based on p16- and/or 
HPV-status outside clinical trials [25].
p16‑status and HPV genotype
Drawing conclusions based on research about HPV-
associated tumors is still challenging, since various and 
inconsistent definitions for a HPV-positive tumor are used 
[16]. For instance, in the RTOG 1016 trial investigating 
radiotherapy combined with cetuximab or cisplatin in 
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HPV-positive oropharyngeal cancer patients, HPV-status 
was determined by p16-overexpression [17]. Other investi-
gators classified only tumors tested positive for HPV-DNA 
as well as HPV-RNA as HPV-positive [22]. Alternatively, 
an algorithm of first p16-immunohistochemistry and for 
positive samples followed by HPV-DNA PCR was applied 
to define “HPV-positivity” [23, 38]. p16-overexpression 
is considered as a surrogate marker for oncogenic HPV-
infection based on the high correlation found between both 
[16, 29].
Within the present study for the distinction between 
p16-positive and p16-negative tumors the criteria sug-
gested for the application of the classification algorithms 
of UICC/AJCC 8th edition was applied [18]. Even though 
concordance between p16- and HPV-status was evident 
in the majority of cases (p16-positive/HPV-positive or 
p16-negative/HPV-negative in 64%), more than one-
third/36% of the OPSCCs showed discordant results of 
either p16-positive/HPV-negative or p16-negative/HPV-
positive characterization. Discordance rates between 
p16-status and HPV-status were also described by others 
with, e.g. 12.7% and 45% [22, 39]. For HPV-detection we 
applied a commercial assay developed for diagnostic pur-
poses that is reported with a sensitivity of 97.5% and spec-
ificity of 93% [30]. Besides the possibility of false-positive 
or false-negative results in HPV-typing, also several other 
factors might have influenced the discordancy detected in 
our cohort: It was described that OPSCCs with a p16-neg-
ative/HPV-positive status demonstrated low amounts of 
HPV-DNA [40]. Thus, it appears possible that p16-posi-
tivity distinguishes samples with different amounts of viral 
DNA, which, in combination with a high sensitivity of the 
multiplex-PCR technique used in the present study, might 
be resulting in the relatively high incidence of p16-nega-
tive/HPV-positive samples. In addition, the herein applied 
PCR uses primers designed for the E6 and E7 loci of the 
HPV genome, which might function as a further influenc-
ing factor [30]. Those regions are most likely to sustain 
after viral integration [30], probably enabling the detec-
tion of not only integrated, but also episomal or mixed 
HPVs. Yamashita et al. examined HPV16 infections and 
found a different distribution between integrated/mixed 
vs. episomal HPV within p16-positive and p16-negative 
OPSCCs. In nearly every of the p16-positive cases HPV 
were completely integrated or mixed, while in p16-nega-
tive OPSCCs HPV was episomal in 55.5% [20]. This indi-
cates that p16-positivity may distinguish cases with episo-
mal versus integrated/mixed HPVs or, in other words, that 
the p16-negative/HPV-positive samples may be tumors 
with episomal HPV, while p16-positive/HPV-positive 
specimens could be the ones with integrated HPVs. Fur-
thermore, reasons for the absence of p16-overexpression 
despite a positive HPV-status (p16-negative/HPV-positive) 
could be genetic (e.g. deletions of the  p16Ink4a gene [41]) 
or due to epigenetic alterations of the p16-gene (e.g. pro-
motor hypermethylation [42]). p16-overexpression with-
out the evidence of HPV (p16-positive/HPV-negative) 
was less likely observed in association with mutations or 
amplifications of the p16-gene (CDKN2A), but was found 
with a higher frequency in case of inactivating mutations 
in the histone H3 lysine 36 methyltransferase, encoded 
by the gene NSD1 [43]. Thus, other factors were already 
linked to p16-overexpression in HPV-negative head and 
neck squamous cell carcinomas (HNSCC). Summarized, 
the molecular basis especially of the discordant subgroups 
requires further research.
Oncological results
Survival based on p16 or HPV status alone
As previously shown, a positive p16-status was associated 
with a superior prognosis of patients with advanced stage 
OPSCCs [26]. Based on these results, the aim of the cur-
rent study was to examine if there were also survival dif-
ferences by stratification based on HPV as a single marker, 
as well as both markers combined. In the current study 
no significant differences with regard to the oncological 
outcome between patients with HPV-positive or negative 
advanced stage OPSCCs was observed. This is in line with 
the results of Park et al. who selectively included patients 
with advanced stage OPSCCs, as well, and described an 
association between OS and p16-status, but non between 
OS and HPV-status [21]. Evaluating patients with stage I-IV 
disease, Yamashita et al. reported at least a trend towards 
superior OS for patients with HPV-positive disease com-
pared to HPV-negative [20]. Hoffmann et al. observed a 
significant higher OS along with a trend towards higher 
progression-free survival for patients with HPV-DNA posi-
tive vs. HPV-DNA negative disease. Their cohort included 
tonsillar SCC alone with 57.1% T1-2 tumors and 30.2% N0 
disease; information about the distribution of prognostic 
stages was not provided [22]. Moreover, after further analy-
sis for HPV-RNA, and stratifying their patients into differ-
ent treatment groups, they observed a significant superior 
OS only between HPV-RNA as well as DNA-positive (their 
definition of HPV-positivity)  and HPV-negative disease 
among patients that had received surgery alone or addi-
tional postoperative chemoradiotherapy, respectively. In 
contrast, among patients treated with postoperative radio-
therapy without chemotherapy, they found no differences 
with regard to the OS between”HPV-positive “(HPV-DNA/
RNA-positive) vs.” HPV-negative “(non-HPV-DNA/RNA-
positive) disease [22]. Thus, following the observations of 
Park et al. [21] and the current study investigating patients 
with advanced disease, the marker HPV indicates a limited 
European Archives of Oto-Rhino-Laryngology 
1 3
prognostic impact. Furthermore, those results of Hoffmann 
et al. considered also tumor’s HPV-RNA status for definition 
of “HPV-positivity” indicated that the survival superiority of 
HPV-positivity may be restricted to patients having received 
different treatment regimes [22].
Notwithstanding, several additional factors could be 
responsible for this heterogenous results of the prognostic 
impact of HPV-presence leading to an aggravated compa-
rability. On the one hand, methodical differences in HPV-
detection, definition of “HPV-positivity” and HPV-genotype 
distribution could have an impact. For instance, a lower sur-
vival for non-HPV16-genotype positive tumors compared 
to HPV16-positivity ones was described [44, 45]. This 
indicates that a prognostic benefit of HPV-positivity may 
be restricted to HPV16 positive tumors. Regarding the pre-
sent study, the presence of 43.9% non-HPV16-genotypes 
(including multiple infections containing HPV16, as well) 
among HPV positive tumors could be a factor that influ-
enced the observed differences in prognostic relevance of 
HPV-presence. Since only 19.5% of the included OPSCCs 
exhibited selectively non-HPV16 genotypes, no further 
subset analysis was performed. In addition, differences in 
the (risk) constitution (e.g. prognostic stages, tobacco and 
alcohol consumption) of the study populations could be rel-
evant for differing results of HPV-positivity on prognosis of 
patients with OPSCCs.
Survival based on p16 and HPV‑status combined
Previous studies already indicated that different constella-
tions of the p16- and HPV-status can define further prog-
nostic divergent subgroups within OPSCCs [19–24]. Nev-
ertheless, studies reporting long-term oncologic results of 
subgroups defined by p16- and HPV-status combined are 
rare [19–24], even though a meta-analysis by Albers et al. 
included 24 studies that investigated the survival of patients 
with HNSCC and evaluated p16- and HPV-status [24]. A 
comparison of our study with this meta-analysis seems lim-
ited due to the following reasons: only 13 of the included 
studies selectively focused on OPSCCs, and only two of 
them provided the 5-year survival estimates of patients 
treated with curative intent, with no cases of distant metas-
tases included [21, 38]. Both studies do not provide the exact 
survival estimates for all four possible subgroups defined 
by p16- and HPV-status [21, 38]. Nevertheless, four more 
recently published studies focused on this topic [19, 20, 22, 
23]. Results are summarized in Table 4.
In the current study, survival estimates (OS, DSS, RFS, 
LCR) of the two p16-positive groups that were either 
HPV-positive or negative showed no significant difference. 
This indicates the same prognostic level of patients with 
p16-positive OPSCCs despite the presence of HPV-DNA. 
This is in line with the results of Yamamoto et al. for a group 
treated with definitive chemoradiotherapy, even though for 
their group treated with definitive radiotherapy alone, they 
observed a significantly superior OS and PFS for patients 
with p16-positive/HPV-positive disease compared to those 
with p16-positive/HPV-negative tumors [19].
In the present study no significant differences among 
patients with p16-negative tumors with or without positive 
HPV-status were observed with regard to OS and LCR. The 
p16-negative/HPV-positive subgroup presented the lowest 
estimates. This is in line with the results of Yamashita et al. 
that also reported higher OS for the group with p16-negative/
HPV-negative status compared to the one with p16-negative/
HPV-positive disease, even though the difference was not 
statistically significant [20]. In the current study the group 
of patients with p16-negative/HPV-positive tumors demon-
strated also lower estimates for DSS and RFS compared to 
patients with concordant negative results. This difference 
reached significance. Other studies did not consider these 
endpoints [19–23].
In contrast to the current study and the one by Yamash-
ita et al. that observed the lowest outcome for the subgroup 
of p16-negative/HPV-positive tumors [20], Hoffmann et al. 
reported the worst survival for the concordant negative 
(p16-negative/HPV-negative) subgroup [22]. Furthermore, 
Nauta et al. reported that patients with p16-positive/HPV-
positive disease showed a significant superior survival 
compared to the group with p16-positive/HPV-negative 
tumors, whose survival differences did not significantly 
differ from patients with p16-negative carcinomas [23], 
even though this study did not further examine p16-nega-
tive tumors with regard to the HPV-status. To our knowl-
edge, Hoffmann et al. and the present study are the only 
studies to date providing data regarding all four subgroups 
and including 5-year survival estimates of patients with 
OPSCCs treated with curative intent (Table 4).
Tobacco consumption
Patients with HPV/p16-associated HNSCCs are described 
to have different risk profiles compared to those with HPV/
p16-negative disease [46]. In particular, tobacco consump-
tion is one factor that is reported to potentially conflict the 
positive impact of HPV/p16-positivity on survival [22]. 
Therefore, distribution as well as the potential prognos-
tic differences within groups with a divergent history of 
tobacco consumption stratified by p16- or HPV-status was 
examined.
In the current study, most of never smoking patients had 
p16-positive disease, whereas the majority of former/current 
smokers exhibited p16-negative tumors. This is in accord-
ance with other studies demonstrating a significant differ-
ing frequency of tobacco history between patients with a 
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p16-positive and p16-negative disease [20, 47]. HPV-pos-
itivity was not differently distributed between never smok-
ing patients and those with a positive history for tobacco 
consumption in the present study. This is in contrast to the 
study of Hoffmann et al., which reports a significant higher 
proportion of > 10 py tobacco consumption among HPV-
negative patients [22].
With regard to survival rates, never smoking patients 
demonstrated superior estimates compared to former/current 
smokers. Considering the tumor’s p16-status, the highest 
survival estimates were observed in never smoking patients 
with p16-positive tumors, whereas patients with p16-pos-
itive disease and a history of smoking had a comparable 
inferior prognosis like p16-negative tumors of former or 
current smokers. This indicates that the superior progno-
sis of p16-positive tumors is abrogated in tobacco consum-
ers. In the present study stratification based on HPV-status 
exhibited no significant differences between the oncological 
results of never and former/current smoking patients. This 
appears to be conflicting with the results of Hoffmann et al., 
demonstrating a negative impact of smoking in patients with 
HPV-positive OPSCC and > 10 py on overall survival. A 
comparable analysis based on p16-status was not mentioned 
in this study [22].
Strengths, limitations and outlook
The relevance of the present study is emphasized by the lack 
of a standardized definition of HPV-association in OPSCCs 
as well as a lack of detailed high-evidence data about the 
implications on the prognosis of the different p16- and HPV-
status constellations. This is reflected by the paucity of stud-
ies, addressing this topic with a focus on long-term onco-
logical outcome of patients with primary OPSCC treated 
with curative intent [19–23]. The limit in data quality and 
a high risk of bias of such retrospective studies also needs 
to be considered in the present one. Nevertheless, we aimed 
to reduce this limitation by implementing strict inclusion 
criteria and by providing detailed clinicopathological data 
obtained from original patients’ charts, surgical and patho-
logical reports as well as an additional pathological assess-
ment. This enabled us to analyze the prognostic implications 
of the p16- and HPV-status separately as well as combined 
in a well-characterized cohort of patients with homogenous 
stage III/IV OPSCC treated exclusively in a surgery-based 
concept. Therefore, the study provides data that will poten-
tially influence the inclusion criteria and analytical scope of 
future, e.g. deintensification trials for HPV-positive disease.
The impact of different HPV-genotypes on prognosis and 
their association with p16-overexpression was not further 
evaluated due to their limited frequency in the present study. 
This topic should be investigated by multicentered studies 
performed prospectively or at least by pooling the already 
existing data of well-described retrospective cohorts.
Conclusion
The current data indicate that p16- and HPV-status should 
not be considered as equivalent markers for a better prog-
nosis in OPSCC. Furthermore, they should not outweigh 
patient-associated prognostic factors like smoking. Thus, 
further studies focusing on therapeutic regimes and prog-
nosis of OPSCC should consider both markers and provide 
detailed information on tobacco consumption.
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